Skip to content
Psychiatrist.com Logo
  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Advanced Search

Menu

  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Sign in Subscribe

Clinical Topics

View All
  • Addiction
  • ADHD
  • Alzheimer’s Disease
  • Anxiety
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Neurology
  • OCD
  • Psychopharmacology
  • PTSD and Trauma
  • Schizophrenia/Schizoaffective Disorders
  • Sleep
  • Tardive Dyskinesia
  • View All

Collections

View All
  • Academic Highlights
  • Auvelity: Information from Industry
  • Banner Alzheimer’s Institute
  • Clinical & Practical Psychopharmacology
  • Early Career Psychiatrists
  • Focus on Childhood and Adolescent Mental Health
  • Focus on Geriatric Psychiatry
  • Focus on Psychotherapy
  • Focus on Suicide
  • Focus on Psychosis
  • Focus on Women’s Mental Health
  • Rounds in the General Hospital
  • UZEDY: Information from Industry
  • View All
Back to top Open menu arrow
Download PDF Reprints
No sections available

The Primary
Care Companionfor CNS Disorders

Free access
Schizophrenia/Schizoaffective Disorders

Original Research June 15, 2005

CME Article: The Relation Between Body Fat Distribution and Cardiovascular Risk Factors in Patients With Schizophrenia: A Cross-Sectional Pilot Study

Martha M. Lato; M. Beatriz Currier; Oscar Villaverde; Mercedes Gonzalez-Blanco

Prim Care Companion J Clin Psychiatry 2005;7(3):115-118

Article Abstract
Schizophrenia Weight Cardiovascular Health

About the Authors

  • Martha M. Lato
    View full profile
  • M. Beatriz Currier
    View full profile
  • Oscar Villaverde
    View full profile
  • Mercedes Gonzalez-Blanco
    View full profile
Download Free PDF

This PDF is free for all visitors!

Related News Articles

Schizophrenia Costs Surge Past $367 Billion in 2024 Single-Gene Mutation Appears to Drive Early-Onset Schizophrenia New Clues Why Schizophrenia Patients Hear Voices
Announcement: The Journal of Clinical Psychiatry launches a new podcast. Click to learn more.

Related JCP Articles

Rationale for Clozapine Trial The Position of Clozapine in Patients with Treatment-Resistant Schizophrenia: Reply to Mattes Developing Algorithmic Psychiatry with Michael Halassa MD, PhD

Related PCC Articles

Cotard Syndrome in Schizophrenia Psychosis Screening in Genetic Disorders Clozapine Withdrawal–Induced Catatonia
Figure: Journal cover summarizes articles on suicide impact, gender-affirming care, drone trauma, veteran toxins, and prenatal substance use.

Vol 27 • 2025 • Number 6

Read the Current Issue

Original Research

Impact of Patient Suicide on Mental Health Professionals

Review Article

Gender-Affirming Surgery, Gender Dysphoria, and QOL

Rounds in the General Hospital

Psychological Sequelae of Drone Attacks

Rounds in the General Hospital

Sequelae of Toxic Exposures in Veterans

Rounds in the General Hospital

Talking to Pregnant Patients About Substance Use

Case Report

Tetrabenazine-Induced Suicidality

View current Issue

Related Articles

JCP
Olanzapine/Samidorphan Effects on Weight Gain
Original Research

Olanzapine/Samidorphan Effects on Weight Gain

January 2, 2025

Treatment with a combination of olanzapine and samidorphan was associated with less weight gain and reduced risk of reaching ≥7% or ≥10% gain in body weight versus olanzapine over...
Christoph U. Correll, Michael J. Doane, David McDonnell, et al
JCP
Long-Term Safety and Treatment Effect of Olanzapine/Samidorphan
Original Research

Long-Term Safety and Treatment Effect of Olanzapine/Samidorphan

December 4, 2024

During up to 4 years of treatment, the combination of olanzapine/samidorphan was safe and well-tolerated, and patients’ symptoms remained stable.
Jacob S. Ballon, René S. Kahn, Christina Arevalo, et al
JCP
Aripiprazole Lauroxil Initiation Regimens
Original Research

Aripiprazole Lauroxil Initiation Regimens

August 12, 2024

In separate studies of the two initiation methods, the numbers of people who had side effects were similar, and most side effects were mild.
Roger W. Sommi, Stephen R. Saklad, Peter J. Weiden, et al

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

ELSEWHERE:

  • ABOUT
  • ADVERTISERS
  • MEDIA RELATIONS
  • REPRINTS & PERMISSIONS
  • CONTACT US
  • CUSTOMER SUPPORT

FOLLOW US:

  • X
  • FACEBOOK
  • INSTAGRAM
  • LINKEDIN
  • THREADS
  • BLUESKY
  • SIGN IN

  • JOIN THE EMAIL LIST


SUBSCRIBE NOW
An image of the Psychiatrist.com logo mark
  • Privacy Policy
  • Terms of Use
  • Physicians Postgraduate Press, Inc.
  • JCP ISSN: Online 1555-2101, Print 0160-6689
  • PCC ISSN: Online 2155-7780, Print 2155-7772
  • MedFair.com US Patent No. 684794
  • © Copyright 2026 | Physicians Postgraduate Press, Inc. | LifeLong Learning For Clinicians
  • Sitemap